Definitive Healthcare (NASDAQ:DH - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.190-0.220 for the period, compared to the consensus EPS estimate of 0.290. The company issued revenue guidance of $230.0 million-$240.0 million, compared to the consensus revenue estimate of $241.2 million. Definitive Healthcare also updated its Q1 2025 guidance to 0.020-0.020 EPS.
Definitive Healthcare Stock Performance
Definitive Healthcare stock traded down $0.40 during mid-day trading on Monday, reaching $2.83. The company's stock had a trading volume of 1,413,851 shares, compared to its average volume of 946,036. The company has a market capitalization of $326.93 million, a P/E ratio of -0.91, a PEG ratio of 4.06 and a beta of 1.45. The firm's fifty day moving average price is $4.63 and its two-hundred day moving average price is $4.48. Definitive Healthcare has a 12-month low of $2.58 and a 12-month high of $9.11. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49.
Definitive Healthcare (NASDAQ:DH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.04). The company had revenue of $62.29 million during the quarter, compared to analysts' expectations of $60.60 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. Sell-side analysts predict that Definitive Healthcare will post 0.16 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have recently commented on DH. Barclays cut their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research report on Monday. Needham & Company LLC reissued a "hold" rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Finally, Stephens assumed coverage on shares of Definitive Healthcare in a research report on Friday, December 20th. They set an "equal weight" rating and a $5.00 price target for the company. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $5.61.
Read Our Latest Stock Analysis on DH
Insider Transactions at Definitive Healthcare
In other Definitive Healthcare news, insider William Moschella sold 45,000 shares of the company's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the completion of the sale, the insider now owns 433,830 shares of the company's stock, valued at $2,039,001. This represents a 9.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 14.84% of the stock is currently owned by insiders.
Definitive Healthcare Company Profile
(
Get Free Report)
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
Recommended Stories
Before you consider Definitive Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definitive Healthcare wasn't on the list.
While Definitive Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
